Revumenib safe, effective in AML related to NPM1 mutations
Oral therapy revumenib showed positive results in patients with relapsed or refractory acute myeloid leukemia (AML) driven by NPM1 mutations, with nearly half of participants…
News
Adding VCN-01 extends survival in metastatic pancreatic cancer trial
Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC),…
Viralgen, Trogenix collaborate on glioblastoma treatment
Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy…
World Ovarian Cancer Day to be observed May 8
Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.
Linvoseltamab, now Lynozyfic, earns EU’s conditional OK to treat RRMM
The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).
EU committee recommends fixed-duration Calquence combo for CLL
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia…
FDA OKs clinical testing of oral treatment for pancreatic cancer
The U.S. Food and Drug Administration (FDA) has given Verastem Oncology the green light to start clinical testing of its oral treatment candidate VS-7375…
Supporters to #GoGrayinMay for Brain Tumor Awareness Month
Each May marks Brain Tumor Awareness Month, with annual efforts to raise awareness about glioma and other types of cancer that affect the brain.
Tepylute for breast, ovarian cancer launched in US
Tepylute (thiotepa), a chemotherapy medication from Shorla Oncology that was approved last year for treating certain breast and ovarian cancers, has launched in the…
Trial data for 2 Caribou CAR T-cell therapies due this year
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
